Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Development of a novel CD19/BCMA dual CAR-T for autoimmune diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

WDWen DingDMDonghui MaMLMin Luo

Discussion

Loading...

Member takes

Overview

This research demonstrates enhanced cytotoxicity in treating autoimmune diseases, indicating potential for safer CAR-T therapies.

Key Points

  • Enhanced cytotoxicity against pathogenic immune cells improves remission in autoimmune diseases.
  • Key findings include reduced adverse effects like cytokine release syndrome for the dual-target CAR-T.
  • Development included novel antibodies and LNP-mRNA-based engineering for T cell safety.
  • Future clinical trials will assess the efficacy of this innovative CAR-T in autoimmune disease treatment.

Cite This Study

Ding et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d911https://doi.org/10.1182/blood-2025-7639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025
  2. 2BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  3. 3CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma2025 · 1 citations
  4. 4Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  5. 5[Next-generation CAR gene-modified cell therapy: overcoming resistance and exploring novel applications].2025